Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 13;7(7):e1442167. doi: 10.1080/2162402X.2018.1442167

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 7. — DACH1/CXCL1 regulation of PMN-MDSC accumulation in patients with ESCC undergoing metformin treatment could improve prognosis. CXCL1 expression was verified in tumor tissues and serum from patients with ESCC using qRT-PCR and ELISA. (B) DACH1 expression in patients with ESCC treated with metformin was measured by qRT-PCR and western blotting. (C) Paired analysis of CXCL1 and DACH1 expression in patients receiving metformin treatment. (D) Two representative ESCC samples showing expression patterns of CXCL1 and DACH1. (E) Overall survival of patients with ESCC showing high and low CXCL1 (n = 104; top) and DACH1 expression (n = 105, bottom), presented as a Kaplan-Meier curve. (F)) Expression of DACH1 and CXCL1 was detected using immunohistochemistry. Data show distribution of DACH1 expression in CXCL1-high and CXCL1-low groups. (G) Overall survival of patients with ESCC displaying differential expression of DACH1 and CXCL1, presented as a Kaplan-Meier curve. (H) Schematic representation of the mechanisms of the anti-tumor effects of metformin. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.